drugset / Trial / NCT00767754

Changes of Cerebral Glucose Metabolism After 12 Weeks of Paroxetine Treatment in Panic Disorder

NCT00767754

Phase 4 Completed 37 enrolled Samsung Medical Center
NaSingle-groupOpen-labelTreatment

Summary

Panic disorder is one of the most prevalent and disabling psychiatric disorders. Brain regions such as amygdala, hippocampus, periaqueductal gray (PAG), locus coeruleus, parahippocampal gyrus, frontal cortex, and thalamus has been reported to be related with the pathophysiology and treatment outcome in panic disorder. Paroxetine has been used as primary agent for treatment of panic disorder but there is little information on how paroxetine affects the brain function in patients with panic disorder. The specific aim of this study is to examine the differences in brain activity between responders and nonresponders and to determine the predictor of paroxetine treatment in patients with panic disorder in terms of brain activity.

Timeline

Start
2007-01
Primary completion
2007-06
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Paroxetine Small molecule 20 mg
Subject Paroxetine Small molecule 40 mg

Indications